TW252044B
(sh)
*
|
1992-08-10 |
1995-07-21 |
Boehringer Ingelheim Kg |
|
US5877179A
(en)
*
|
1992-09-29 |
1999-03-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
|
WO1994025462A1
(en)
*
|
1993-05-03 |
1994-11-10 |
The United States Of America, Represented By The |
8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
|
DE4316576A1
(de)
*
|
1993-05-18 |
1994-11-24 |
Boehringer Ingelheim Kg |
Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
|
US5646156A
(en)
*
|
1994-04-25 |
1997-07-08 |
Merck & Co., Inc. |
Inhibition of eosinophil activation through A3 adenosine receptor antagonism
|
US5591776A
(en)
|
1994-06-24 |
1997-01-07 |
Euro-Celtique, S.A. |
Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
|
GB9415529D0
(en)
|
1994-08-01 |
1994-09-21 |
Wellcome Found |
Phenyl xanthine derivatives
|
CA2206287C
(en)
*
|
1994-12-13 |
2001-03-20 |
Mark Chasin |
Aryl thioxanthines
|
EP0799040B1
(en)
|
1994-12-13 |
2003-08-20 |
Euroceltique S.A. |
Trisubstituted thioxanthines
|
US5864037A
(en)
|
1996-06-06 |
1999-01-26 |
Euro-Celtique, S.A. |
Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
|
GB9623859D0
(en)
*
|
1996-11-15 |
1997-01-08 |
Chiroscience Ltd |
Novel compounds
|
US5786360A
(en)
*
|
1996-11-19 |
1998-07-28 |
Link Technology Incorporated |
A1 adenosine receptor antagonists
|
GB9703044D0
(en)
*
|
1997-02-14 |
1997-04-02 |
Glaxo Group Ltd |
Phenyl xanthine esters and amides
|
US6248746B1
(en)
|
1998-01-07 |
2001-06-19 |
Euro-Celtique S.A. |
3-(arylalkyl) xanthines
|
WO1999031101A1
(en)
*
|
1997-12-17 |
1999-06-24 |
University Of South Florida |
Adenosine receptor antagonists with improved bioactivity
|
DE19816857A1
(de)
*
|
1998-04-16 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
WO2000002861A1
(en)
|
1998-07-10 |
2000-01-20 |
The United States Of America, Represented By Secretary, Department Of Health And Human Services |
A3 adenosine receptor antagonists
|
GB9817623D0
(en)
|
1998-08-13 |
1998-10-07 |
Glaxo Group Ltd |
Pharmaceutical compounds
|
JP2003513982A
(ja)
*
|
1999-11-12 |
2003-04-15 |
バイオジェン インコーポレイテッド |
アデノシンレセプターアンタゴニストとしてのポリシクロアルキルプリン
|
AU784528B2
(en)
|
1999-11-12 |
2006-04-27 |
Biogen Idec Ma Inc. |
Adenosine receptor antagonists and methods of making and using the same
|
WO2001047931A1
(fr)
*
|
1999-12-24 |
2001-07-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Derives de purine fondue
|
US7087589B2
(en)
|
2000-01-14 |
2006-08-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methanocarba cycloakyl nucleoside analogues
|
KR100926247B1
(ko)
*
|
2001-02-24 |
2009-11-12 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
|
UA80258C2
(en)
*
|
2001-09-06 |
2007-09-10 |
Biogen Inc |
Methods of treating pulmonary disease
|
US7495004B2
(en)
|
2002-06-17 |
2009-02-24 |
Glaxo Group Limited |
Purine derivatives as liver X receptor agonists
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7495005B2
(en)
|
2002-08-22 |
2009-02-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, their preparation and their use in pharmaceutical compositions
|
US7569574B2
(en)
|
2002-08-22 |
2009-08-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US7482337B2
(en)
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10254304A1
(de)
|
2002-11-21 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
EP1601649A4
(en)
*
|
2003-02-19 |
2009-03-04 |
Endacea Inc |
A1-adenosine receptor antagonistic
|
KR20060004959A
(ko)
|
2003-04-25 |
2006-01-16 |
노바카르디아, 인코포레이션 |
신장 기능 저하를 갖는 개별 대상자의 이뇨 작용 개선 방법
|
JP4859666B2
(ja)
*
|
2003-06-06 |
2012-01-25 |
エンダセア, インコーポレイテッド |
A1アデノシンレセプターアンタゴニスト
|
WO2004110379A2
(en)
*
|
2003-06-09 |
2004-12-23 |
Endacea, Inc. |
A1 adenosine receptor antagonists
|
US7566707B2
(en)
|
2003-06-18 |
2009-07-28 |
Boehringer Ingelheim International Gmbh |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10355304A1
(de)
*
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
DE102004009039A1
(de)
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
|
US7393847B2
(en)
|
2004-03-13 |
2008-07-01 |
Boehringer Ingleheim International Gmbh |
Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
|
US7179809B2
(en)
*
|
2004-04-10 |
2007-02-20 |
Boehringer Ingelheim International Gmbh |
2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
|
US7439370B2
(en)
|
2004-05-10 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
DE102004043944A1
(de)
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004044221A1
(de)
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
NZ573360A
(en)
|
2006-05-04 |
2012-08-31 |
Boehringer Ingelheim Int |
Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
WO2008017670A1
(en)
*
|
2006-08-08 |
2008-02-14 |
Boehringer Ingelheim International Gmbh |
Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
|
EP2190434B1
(en)
*
|
2007-08-17 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Purin derivatives for use in the treatment of fap-related diseases
|
JP5603248B2
(ja)
|
2007-12-21 |
2014-10-08 |
エンダセア, インコーポレイテッド |
A1アデノシン受容体アンタゴニスト
|
US7928259B2
(en)
*
|
2008-02-12 |
2011-04-19 |
Frx Polymers, Inc. |
Diaryl alkylphosphonates and methods for preparing same
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
JP5906086B2
(ja)
*
|
2008-08-15 |
2016-04-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Fab関連疾患の治療に用いるためのプリン誘導体
|
JP2012502081A
(ja)
|
2008-09-10 |
2012-01-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連症状の治療のための組み合わせ治療
|
JP5334511B2
(ja)
*
|
2008-09-22 |
2013-11-06 |
日本精化株式会社 |
化粧料
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
TWI508965B
(zh)
|
2008-12-23 |
2015-11-21 |
Boehringer Ingelheim Int |
有機化合物的鹽形式
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
CN102361557A
(zh)
*
|
2009-03-26 |
2012-02-22 |
Mapi医药公司 |
制备阿格列汀的方法
|
JP2013512229A
(ja)
|
2009-11-27 |
2013-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療
|
WO2011068978A1
(en)
|
2009-12-02 |
2011-06-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methanocarba adenosine derivatives and dendrimer conjugates thereof
|
NZ602921A
(en)
|
2010-05-05 |
2016-01-29 |
Boehringer Ingelheim Int |
Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
|
MX2012014247A
(es)
|
2010-06-24 |
2013-01-18 |
Boehringer Ingelheim Int |
Terapia para la diabetes.
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
EP3517539B1
(en)
|
2011-07-15 |
2022-12-14 |
Boehringer Ingelheim International GmbH |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
EP3468562A1
(en)
|
2016-06-10 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Combinations of linagliptin and metformin
|
RU2643336C1
(ru)
*
|
2016-10-03 |
2018-01-31 |
Общество с Ограниченной Ответственностью "Компания "ЭЛТА" |
СРЕДСТВО, ПРОЯВЛЯЮЩЕЕ АНТИТРОМБОТИЧЕСКИЙ ЭФФЕКТ ПОСРЕДСТВОМ БЛОКИРОВАНИЯ РЕЦЕПТОРОВ ТРОМБОЦИТОВ ГП IIb-IIIa (ВАРИАНТЫ)
|
CN109796453A
(zh)
*
|
2019-02-12 |
2019-05-24 |
南京纽邦生物科技有限公司 |
一种1,7-二甲基黄嘌呤的制备方法
|
WO2022079245A1
(en)
|
2020-10-15 |
2022-04-21 |
Rheinische-Friedrich-Wilhelms-Universität Bonn |
3-substituted xanthine derivatives as mrgprx4 receptor modulators
|